RESEARCH ARTICLE
Technology Development Through Pooling ARV Drug Patents: A Vision from China
Li Liu1, Hongzhou Lu1, 2, *
1 Department of Infectious Disease, Shanghai Public Health Clinical Center Affiliated to Fudan University, Shanghai, 201508, China
2 Department of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, 00040, China
Article Information
Identifiers and Pagination:
Year: 2010Volume: 4
First Page: 54
Last Page: 59
Publisher ID: TOAIDJ-4-54
DOI: 10.2174/1874613601004020054
Article History:
Received Date: 26/2/2009Revision Received Date: 2/3/2009
Acceptance Date: 1/7/2009
Electronic publication date: 19/1/2010
Collection year: 2010
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Abstract
Unaffordable prices still bar the end-users in China from accessing ARV drugs. Patent protection of ARV drugs has dramatically limited the availability of these lifesaving drugs to AIDS patients in China.
The way Chinese government can go to breakthrough the ARV drug patents are suggested as:
- Make more generic drugs available through compulsory licensing, impartment from other countries or building ARVs plants by partnerships between governments or generic drug companies.
- Do a thorough and detailed research on the patent application of ARV drugs to find out the loophole.
- Try patent pool to make AIDS medicines more affordable and appropriate for patients.
